Results 221 to 230 of about 61,437 (248)

DNA Topoisomerase I Inhibitors from Rinorea anguifera.

ChemInform, 2005
AbstractFor Abstract see ChemInform Abstract in Full Text.
Ji, Ma, Shannon H, Jones, Rebekah, Marshall, Xihan, Wu, Sidney M, Hecht   +4 more
openaire   +2 more sources

Dual topoisomerase I/II inhibitors

Journal of Oncology Pharmacy Practice, 2000
Topoisomerase (topo) I and II are nuclear enzymes, which play a major role in the topological rearrangement of DNA during replication and transcription processes. In the course of years, many different agents have been found which can inhibit the topos and thereby exploit cytotoxicity, also against tumour cells.
R. van Gijn, R.R.H. Lendfers, J.H.M. Schellens, A. Bult, J.H. Beijnen   +4 more
openaire   +1 more source

3-Arylisoquinolines as novel topoisomerase I inhibitors

Bioorganic & Medicinal Chemistry, 2011
Topoisomerase I (topo I) is an essential enzyme for vital cellular processes. Inhibition of topo I activities is lethal and leads to cell death, thus establishing topo I as a promising target for cancer treatment. Camptothecin, a natural alkaloid, inhibits topo I.
Daulat Bikram, Khadka, Won-Jea, Cho
openaire   +2 more sources

β-Carbolinedione Derivatives as Topoisomerase I Inhibitors

Archiv der Pharmazie, 1999
Pyrrolo[3,4-c]-beta-carbolinedione dimers 5-14 were synthesized from furo[3,4-c]-beta-carbolinediones and diamines by solvent-free TaCl5/silica catalyzed reaction under microwave irradiation. The inhibitory property of these target compounds, the starting materials 2, 31, 32, and the N-alkylated pyrrolo[3,4-c]-beta-carbolinediones 16, 17, 20-30 was ...
S, Mahboobi, S, Eluwa, S, Kumar, M, Koller, K, Störl   +4 more
openaire   +2 more sources

Toxicity of the topoisomerase II inhibitors

Expert Opinion on Drug Safety, 2005
The topoisomerase I inhibitors represent a class of antineoplastic agents with a wide spectrum of activity against malignancies. Currently available topo-isomerase I inhibitors are derivatives of the parent compound, camptothecin. Irinotecan is most active against gastrointestinal (GI) tumours, and has predominantly GI and haematological toxicities ...
openaire   +3 more sources

Topoisomerase I inhibitors: selectivity and cellular resistance

Drug Resistance Updates, 1999
Topoisomerase I (top1) inhibitors (camptothecins and other structurally diverse compounds) are effective and promising anticancer agents. Determinants of selectivity toward cancer cells and resistance are multifactorial. These factors can be separated in three groups. The first is related to alterations in drug distribution and metabolism.
Pommier, Yves, Pourquier, Philippe, Urasaki, Yoshimasa, Wu, Jiaxi, Laco, Gary   +4 more
openaire   +3 more sources

Novel camptothecin derivatives as topoisomerase I inhibitors

Expert Opinion on Therapeutic Patents, 2009
Camptothecin (CPT), a pentacyclic alkaloid isolated by Wall et al. in 1958 from the Chinese tree Camptotheca acuminata, was reported to possess an interesting antitumor activity. Late in 1985, it was reported by Liu et al. that the cytotoxic activity of CPT was attributed to a novel mechanism of action involving the nuclear enzyme classified as type I ...
BASILI, SERENA, MORO, STEFANO
openaire   +2 more sources

Pyrroloquinolinone-based dual topoisomerase I/II inhibitor

European Journal of Medicinal Chemistry, 2014
A new series of pyrroloquinolinones bearing different alkylamino side chains were synthesized and evaluated as cytotoxic compounds against three different human tumor cell lines (HeLa, HL-60 and A431). Some compounds showed interesting antiproliferative activity, in particular against A431 cells.
DALLA VIA, LISA, MARZARO, GIOVANNI, FERRARESE, ALESSANDRO, GIA, ORNELLA MARIA, CHILIN, ADRIANA   +4 more
openaire   +3 more sources

Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors

Bioorganic & Medicinal Chemistry Letters, 2004
AbstractFor Abstract see ChemInform Abstract in Full Text.
Andrew, Morrell, Smitha, Antony, Glenda, Kohlhagen, Yves, Pommier, Mark, Cushman   +4 more
openaire   +2 more sources

Preclinical and phase I trials of topoisomerase I inhibitors

Cancer Chemotherapy and Pharmacology, 1994
A total of three topoisomerase I inhibitors, including topotecan, CPT-11 (irinotecan), and intoplicine, have been studied in both preclinical and clinical/clinical pharmacology studies. In in vitro testing against human tumor colony-forming units, all three compounds were significantly more effective when tested as a continuous exposure as compared ...
D D, Von Hoff, H A, Burris, J, Eckardt, M, Rothenberg, S M, Fields, S F, Chen, J G, Kuhn   +6 more
openaire   +2 more sources